EMIT Imaging

Executive Summary

EMIT Imaging is a Cambridge-based preclinical imaging company that has developed and commercialized Cryo-Fluorescence Tomography (CFT) technology through its Xerra™ platform. The system enables high-resolution, high-sensitivity 3D volumetric imaging of whole animals, allowing researchers to visualize drug biodistribution, protein expression, and biochemical processes. Founded in 2016, the company serves the drug discovery and development sector by offering both instrument sales and imaging services. Its technology addresses a critical need for non-invasive, quantitative imaging in preclinical studies, providing deeper insights into pharmacokinetics and pharmacodynamics compared to traditional methods. The company operates in a growing preclinical imaging market, driven by increasing R&D spending in biopharma and the demand for more predictive preclinical models. EMIT Imaging is privately held and has not disclosed funding or valuation, but its technology has the potential to become a standard tool in drug development. Key competitive advantages include whole-body imaging without the need for sectioning, high sensitivity, and rapid scanning times. The company is well-positioned to capture market share from established modalities like MRI and PET in certain applications, especially where cost and throughput are critical. Near-term success depends on commercial adoption and strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026First commercial installation of Xerra platform70% success
• Q4 2026Strategic partnership with major pharmaceutical company50% success
• Q2 2026Expansion of imaging services to new contract research organizations80% success